ReviewFuture medicinal chemistry2017
α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease.
Review in Future medicinal chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Research Progress on the Application of Mass Spectrometry Imaging Technology in Cerebral Disease.Life (Basel, Switzerland) · 2026Review
- Exploring Acoustic Detection of α-Synuclein Fibrils.The protein journal · 2025Article
- Extraction, isolation, synthesis, and biological evaluation of novel piperic acid derivatives for the treatment of Alzheimer's disease.Molecular diversity · 2024Article
- Effect of exercise on sleep quality in Parkinson's disease: a mini review.BMC neurology · 2024Review
- The 75-99 C-Terminal Peptide of URG7 Protein Promotes α-Synuclein Disaggregation.International journal of molecular sciences · 2024Article
- Elevated concentrations cause upright alpha-synuclein conformation at lipid interfaces.Nature communications · 2023Article
- DPP-4 inhibitors and type 2 diabetes mellitus in Parkinson's disease: a mutual relationship.Pharmacological reports : PR · 2023Review
- Mechanistic Insights into Polyphenols' Aggregation Inhibition of α-Synuclein and Related Peptides.ACS chemical neuroscience · 2023Article
- Ligand-Based Discovery of a Small Molecule as Inhibitor of α-Synuclein Amyloid Formation.International journal of molecular sciences · 2022Article
- Autophagy and Its Association with Genetic Mutations in Parkinson Disease.Medical science monitor : international medical journal of experimental and clinical research · 2022Review
- Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson's disease.Frontiers in pharmacology · 2022Review
- Could Small Heat Shock Protein HSP27 Be a First-Line Target for Preventing Protein Aggregation in Parkinson's Disease?International journal of molecular sciences · 2021Review
- Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson's disease.Journal of enzyme inhibition and medicinal chemistry · 2020Article
- Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization.Scientific reports · 2020Article
- Anti-aggregation Effects of Phenolic Compounds on α-synuclein.Molecules (Basel, Switzerland) · 2020Review
- Is insulin-like growth factor-1 involved in Parkinson's disease development?Journal of translational medicine · 2020Review
- Insights Into Peptide Inhibition of Alpha-Synuclein Aggregation.Frontiers in neuroscience · 2020Article
- Dynamic behaviors of α-synuclein and tau in the cellular context: New mechanistic insights and therapeutic opportunities in neurodegeneration.Neurobiology of disease · 2019Review
- A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer's and Parkinson's diseases.Molecular diversity · 2019Review
- C-Terminal Truncated α-Synuclein Fibrils Contain Strongly Twisted β-Sheets.Journal of the American Chemical Society · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Parkinson's disease (PD) is a multifactorial progressive neurological disorder. Pathological hallmarks of PD are characterized by the presence of α-synuclein (αSyn) aggregates known as Lewy bodies. αSyn aggregation is one of the leading causes for the neuronal dysfunction and death in PD. It is also associated with neurotransmitter and calcium release. Current therapies of PD are limited to only symptomatic relief without addressing the underlying pathogenic factors of the disease process such as aggregation of αSyn. Consequently, the progression of the disease continues with the current therapies. Therefore, the modulation of αSyn aggregation is an emerging approach as a novel therapeutic target to treat PD. There are two major aspects that might be targeted therapeutically: first, protein is prone to aggregation, therefore, anti-aggregative or compounds that can break the pre-existing aggregates should be helpful. Second, there are number of molecular events that may be targeted to combat the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.